Title
Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication
Authoring Organizations
Publication Month/Year
May 15, 2024
Last Updated Month/Year
November 25, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy.
Target Patient Population
Pregnant women with epilepsy
PICO Questions
What is the prevalence of major congenital malformations (MCMs) associated with intrauterine exposure to specific anti-seizure medications (ASMs), and how does this vary between ASMs in monotherapy versus polytherapy, and at high doses versus low-to-medium doses of ASMs, in children born to pregnant women with epilepsy and concomitant psychiatric disorders (PWECP)?
What is the prevalence of adverse perinatal outcomes associated with intrauterine exposure to specific anti-seizure medications (ASMs), and how does this vary between ASMs in monotherapy versus polytherapy, and at high doses versus low-to-medium doses of ASMs, in children born to pregnant women with epilepsy and concomitant psychiatric disorders (PWECP)?
What is the prevalence of adverse neurodevelopmental outcomes associated with intrauterine exposure to specific anti-seizure medications (ASMs), and how does this vary between ASMs in monotherapy versus polytherapy, and at high versus low-to-medium doses of ASMs, in children born to pregnant women with epilepsy and concomitant psychiatric disorders (PWECP)?
What is the effect of intrauterine exposure to folic acid on the prevalence of major congenital malformations (MCMs), adverse perinatal outcomes, and neurodevelopmental outcomes, and how does this vary by folic acid dose in children born to pregnant women with epilepsy and concomitant psychiatric disorders (PWECP) treated with anti-seizure medications (ASMs)?
Inclusion Criteria
Adolescent, Adult
Health Care Settings
Ambulatory, Hospital, Outpatient, Operating and recovery room
Intended Users
Nurse, nurse practitioner, occupational therapist, physician, physician assistant
Scope
Management
Diseases/Conditions (MeSH)
D004827 - Epilepsy, D018743 - Perinatal Care, D064793 - Teratogenesis
Keywords
antiepileptic drug, women with epilepsy, Teratogenesis, perinatal outcomes
Source Citation
Pack AM, Oskoui M, Williams Roberson S, et al. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: Practice guideline from the AAN, AES, and SMFM. Neurology. 2024;102(11). doi:10.1212/WNL.0000000000209279